Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes
Status:
Completed
Trial end date:
2019-08-16
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the mechanism behind the anti-atherogenic effects
of liraglutide.
In a randomized, placebo-controlled, double-blind, parallel trial we will included 100
patients with type 2 diabetes. Patients will be randomized 1:1 to an active treatment period
of 26 weeks or placebo for 26 weeks.
The primary endpoint is change from baseline to week 26 in vascular inflammation, assessed by
Flour Deoxy Glucose (FDG)-Positron Emission Tomography/Computed Tomography (PET/CT)
Phase:
Phase 4
Details
Lead Sponsor:
Steno Diabetes Center Steno Diabetes Center Copenhagen
Collaborator:
Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet & Cluster for Molecular Imaging, University of Copenhagen, Denmark